In cancer, particularly hepatocellular carcinoma (HCC), high SPTBN1 expression is associated with poor prognosis, positioning it as a potential biomarker and therapeutic target (Rao et al. 2021). This evidence concerns the gene SPTBN1 and hepatocellular carcinoma.